Jennifer Hibma
Pfizer (United States)(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Multiple Myeloma Research and Treatments, Monoclonal and Polyclonal Antibodies Research, Acute Lymphoblastic Leukemia research, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin(2015)58 cited
- → Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection(2020)35 cited
- → Pharmacokinetic/Pharmacodynamic Modeling to Support the Re‐approval of Gemtuzumab Ozogamicin(2019)35 cited
- → Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung Cancer(2021)25 cited
- → Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia(2018)22 cited
- → Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib(2020)17 cited
- → Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc‐concentration modelling(2018)14 cited
- → Clinical Pharmacology Worldwide: A Global Health Perspective(2021)14 cited
- → Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma(2022)13 cited
- → Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants(2021)11 cited